The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 24, 2024

Filed:

Oct. 18, 2019
Applicant:

Sinomab Bioscience Limited, Pak Shek Kok, HK;

Inventor:

Shui-On Leung, New Territories, HK;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 9/00 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61P 19/02 (2006.01); A61P 35/00 (2006.01); A61P 37/06 (2006.01); C07K 14/705 (2006.01); G01N 33/68 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2803 (2013.01); A61K 9/0019 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61P 19/02 (2018.01); A61P 35/00 (2018.01); A61P 37/06 (2018.01); C07K 14/70503 (2013.01); G01N 33/68 (2013.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); C07K 2317/34 (2013.01); C07K 2317/56 (2013.01); C07K 2317/76 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01); C07K 2319/00 (2013.01); G01N 2333/70503 (2013.01); G01N 2500/02 (2013.01); G01N 2500/10 (2013.01);
Abstract

A method for restoring immune control over autoimmunity in a subject in need thereof is described. The method comprises the step of administering to the subject a therapeutically effective amount of an antibody that disrupts Siglec-binding in cis. A method of screening for an antibody that is disruptive of Siglec binding in cis, a method of making an antibody for restoring immune control over autoimmunity to a subject in need, a method of modulating autoimmunity in an immune cell and a method of releasing sialic acid binding site of human CD22 from cis-binding configuration to trans-ligand formation in treating autoimmunity in a subject in need thereof are also described. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also disclosed herein.


Find Patent Forward Citations

Loading…